Annals of the New York Academy of Sciences
-
Ann. N. Y. Acad. Sci. · Oct 2009
AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. ⋯ Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.